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Pyridoxamine lowers kidney crystals in experimental hyperox-
aluria: A potential therapy for primary hyperoxaluria.
Background. Primary hyperoxaluria is a rare genetic disor-
der of glyoxylate metabolism that results in overproduction of
oxalate. The disease is characterized by severe calcium oxalate
nephrolithiasis and nephrocalcinosis, resulting in end-stage re-
nal disease (ESRD) early in life. Most patients eventually
require dialysis and kidney transplantation, usually in combina-
tion with the replacement of the liver. Reduction of urinary ox-
alate levels can efficiently decrease calcium oxalate depositions;
yet, no treatment is available that targets oxalate biosynthesis.
In previous in vitro studies, we demonstrated that pyridoxamine
can trap reactive carbonyl compounds, including intermediates
of oxalate biosynthesis.
Methods. The effect of PM on urinary oxalate excretion and
kidney crystal formation was determined using the ethylene gly-
col rat model of hyperoxaluria. Animals were given 0.75% to
0.8% ethylene glycol in drinking water to establish and main-
tain hyperoxaluria. After 2 weeks, pyridoxamine treatment
(180 mg/day/kg body weight) started and continued for an ad-
ditional 2 weeks. Urinary creatinine, glycolate, oxalate, and cal-
cium were measured along with the microscopic analysis of
kidney tissues for the presence of calcium oxalate crystals.
Results. Pyridoxamine treatment resulted in significantly
lower (by ∼50%) levels of urinary glycolate and oxalate ex-
cretion compared to untreated hyperoxaluric animals. This was
accompanied by a significant reduction in calcium oxalate crys-
tal formation in papillary and medullary areas of the kidney.
Conclusion. These results, coupled with favorable toxicity
profiles of pyridoxamine in humans, show promise for thera-
peutic use of pyridoxamine in primary hyperoxaluria and other
kidney stone diseases.
Primary hyperoxaluria is a rare autosomal-recessive
disorder of glyoxylate metabolism that results in over-
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production of oxalate. The most severe form of the dis-
ease is primary hyperoxaluria type 1 characterized by
the absence or deficiency of the liver peroxisomal en-
zyme alanine:glyoxylate aminotransferase (AGT), which
catalyses the transamination of glyoxylate to glycine us-
ing pyridoxal phosphate as coenzyme (Fig. 1). A num-
ber of mutations have been identified in AGT, which
are associated with inhibition of coenzyme binding, ac-
celerated degradation, aggregation, or pyroxisome-to-
mitochondrion mistargeting [1]. Most commonly, the
disease is characterized by severe calcium oxalate
nephrolithiasis and nephrocalcinosis, resulting in end-
stage renal disease (ESRD) early in life [2]. A decline
in glomerular filtration leads to the deposition of cal-
cium oxalate in almost every tissue throughout the body.
A minority of the patients with a milder course of the
disease, which, presumably, carries a mutation associ-
ated with residual AGT activity, can be at least partially
treated with pharmacologic amounts of pyridoxine [3].
However, most patients eventually require dialysis and
kidney transplantation, usually in combination with the
replacement of the liver [2]. A second form of the disease,
primary hyperoxaluria type 2 is caused by a deficiency of
enzyme glyoxylate reductase/hydroxypyruvate reductase
[4]. It is almost always milder than primary hyperoxaluria
type 1 but still manifests nephrolithiasis and sometimes
renal failure [5].
Deposition of calcium oxalate is also observed in idio-
pathic kidney stone disease where it accounts for ∼70%
of stones formed [6]. This multifactorial disease affects
about 2% to 3% of general population in the industrial-
ized countries and is often accompanied by hyperoxaluria
[7]. Although, the extracorporeal shock wave lithotripsy
has significantly simplified kidney stone removal, the re-
currence rates remain high, reaching 50% to 70% in
10 years [8, 9].
The control of concentrations of oxalate and/or cal-
cium in urine is an important part of medical treatment
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Fig. 1. Glyoxylate pathway of oxalate biosynthesis in liver [42]. 1 is
aldehyde dehydrogenase; 2 is glycolate oxidase; 3 is lactate dehydroge-
nase; and 4 is glyoxylate reductase/hydroxypyruvate reductase.
programs designed to inhibit or prevent calcium oxalate
stone formation. In this regard, the lowering of urinary
oxalate level has a number of advantages. In hyperox-
aluria, the contribution of oxalate to calcium oxalate su-
persaturation is considerably greater than that of calcium.
As a result, a relatively small decrease in oxalate con-
centration could lower the calcium oxalate level below
saturation, and thus prevent crystal formation. Dietary
control of oxalate can produce only a partial effect since
a majority of it is synthesized endogenously, mainly in
liver [10, 11] (Fig. 1). In primary hyperoxaluria, contri-
bution of dietary oxalate to urinary oxalate is very small.
However, even in absorptive hyperoxaluria, a reduction
in endogenous oxalate synthesis would decrease total ox-
alate excretion. Thus, oxalate biosynthesis is a potential
target for the design of drug therapy that decreases uri-
nary oxalate. Strategies for reducing calcium excretion,
such as neutral phosphate or citrate ingestion, can further
decrease urinary calcium oxalate supersaturation.
In the present paper, we establish pyridoxamine as a
new prospective therapeutic agent for treatment of pri-
mary hyperoxaluria and idiopathic nephrolithiasis. Pyri-
doxamine, an inhibitor of advanced glycation reactions
[12, 13], was initially proposed for treatment of diabetic
nephropathy. In preclinical and recent phase II clinical
trials, it demonstrated a very favorable toxicity profile
[abstract; Williams ME, et al, J Am Soc Nephrol 14:7A,
2003]. While investigating the pyridoxamine mechanism
of action, we and others have found that pyridoxamine
can scavenge reactive carbonyl products of glucose and
lipid degradation [14–16]. These findings led us to hypoth-
esize that pyridoxamine may also scavenge the carbonyl
intermediates in the glyoxylate pathway and, thus, inhibit
oxalate biosynthesis (Fig. 1). Here, we demonstrate that
pyridoxamine treatment lowers urinary oxalate excretion
and inhibits calcium oxalate crystal formation in the ani-
mal model of experimental hyperoxaluria. These results
show promise for therapeutic use of pyridoxamine in hy-
peroxaluric syndromes and other kidney stone diseases.
METHODS
Reagents
Ethylene glycol, glycolic acid, glycolate oxidase, gly-
oxylic acid, glycolaldehyde, trinitrobenzenesulfonic acid
were purchased from Sigma-Aldrich Co. (St. Louis, MO,
USA). Pyridoxamine was generously provided by BioS-
tratum, Inc. (Durham, NC, USA)
Ethylene glycol model of hyperoxaluria
and pyridoxamine treatment
We employed an established rat model of experimen-
tal hyperoxaluria, the ethylene glycol model [17, 18].
Although rats do not spontaneously develop stones, hy-
peroxaluria can be induced in rats, and, as in humans,
their oxalate synthesis occurs primarily via glyoxylate
pathway [17]. Because ethylene glycol is converted to
glycolaldehyde, an intermediate in glyoxylate pathway, its
administration results in increased urinary oxalate levels
[17, 18] (Fig. 1).
Animal experiments were performed at the
AAALAC-accredited animal facilities at Vanderbilt Uni-
versity Medical Center and University of Kansas Medical
Center according to institutional guidelines and IACUC-
approved experimental protocol. Sprague-Dawley
male rats (49 to 52 days old) (Harlan Bioproducts,
Inc., Indianapolis, IN, USA) were housed individually
and fed standard powdered stock ration (Purina Mill
Inc., St. Louis, MO, USA). The number of animals in
each experiment is indicated in the figure legends. The
temperature was kept at 22 ± 2◦C with the lights set at a
12-hour light/darkness cycle. For uniform administration
of ethylene glycol and pyridoxamine, water supply to
all animals was limited to 45 mL/day. Pyridoxamine
was given to animals in drinking water after a 2-week
adaptation period to establish elevated constant levels of
urinary oxalate excretion in model animals. To minimize
possible chemical degradation of pyridoxamine, a light-
sensitive compound, fresh solution was prepared daily
and administered in water bottles wrapped in aluminum
foil. The length of treatment was determined based on
data by Khan [17], suggesting that after about 35 days
of experimental hyperoxaluria rats may have some
evidence of microscopic nephrolithiasis, but their renal
function remains normal. Animals were randomized on
day 1 to receive either ethylene glycol (0.75% vol/vol
in drinking water) (ethylene glycol group) or water
(control group). After day 14 animals within each group
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(control or ethylene glycol) were pair-matched according
to their urinary oxalate level. One member of each pair
was then randomly assigned to receive pyridoxamine
(3 mg/mL) either in drinking water (pyridoxamine
group) or in 0.75% ethylene glycol (ethylene glycol +
pyridoxamine group). The 24-hour urine samples were
collected in metabolic cages under toluene (to inhibit
bacteria growth) in 50 mL tubes with hydrochloric acid
to minimize spontaneous breakdown of urinary ascorbic
acid to oxalate. The samples were analyzed immediately
or stored at −70◦C until further analysis.
Analysis of urine samples
Urinary oxalate was measured by the oxalate oxidase
method. Briefly, the method is based on the conversion
of oxalate to hydrogen peroxide and carbon dioxide by
oxalate oxidase. The former is then determined enzy-
matically with horseradish peroxidase by oxidative cou-
pling of 3-methyl-2-benzothiazolinone hydrazone with
N,N-dimethylaniline. The resulting colored product is
determined spectrophotometricaly at 595 nm [19]. Uri-
nary calcium was measured using the Calcium Assay Kit
(Diagnostic Chemical Ltd., Charlottetown, Canada).
Urinary creatinine was determined using the Creatinine
Kit (Sigma-Aldrich Co.) based on the Jaffe´ colorimet-
ric assay, with modifications to improve specificity. Uri-
nary concentration of glycolic acid was determined by the
method described by Petrarulo et al [20]. The method
is based on enzymatic conversion of glycolic acid to
glyoxylic acid followed by derivatization with phenyl-
hydrazone, separation of reaction products by reverse-
phase high performance liquid chromatography (HPLC)
(NovaPack-C18 column) (Waters Co., Milford, MA,
USA), and spectrophotometric detection at 324 nm.
Since high concentration of pyridoxamine may be present
in urine of pyridoxamine-treated animals, we checked if
this would interfere with the analysis of urine samples.
The addition of pyridoxamine to the assay mixtures (fi-
nal concentration of 3 mg/mL) did not affect the readings.
Analysis of oxalate crystal deposition in kidney tissue
Animals were euthanized and the kidneys removed.
For each kidney, two representative hematoxylin-eosin–
stained paraffin sections were prepared on a slide and
slides were coded for blind scoring by two independent
examiners. Slides were examined under the microscope
using low power magnification and moderately polar-
ized light. Each examiner scored sections on a four-point
scale, applying the scale separately to each of the three
anatomic areas of the kidney (papilla, medulla, and cor-
tex). The scoring was 0, no oxalate crystals in any field;
0.5, no more than two crystals in any field; 2, more than
two crystals in any field; and 3, all fields with multiple
collections of crystals. For each slide the scores for the
two sections were averaged, yielding a single score for
papilla, medulla, and cortex of each kidney. For each ani-
mal the scores for the two kidneys were averaged. Finally,
the two examiners’ scores were averaged for each animal.
Interexaminer scoring reliability was taken as the Pear-
son correlation (r) between the examiners. Overall cor-
relation for all three kidney areas was significant (r=0.84,
P < 0.001).
Determination of reactive carbonyl groups
Glyoxylate (10 mmol/L) was incubated either alone
or with 15 mmol/L pyridoxamine. The carbonyl groups
of glyoxylate were determined using 2,3-dinitrophenyl-
hydrazine (DNPH) method [21]. The 20 lL aliquots of
the samples were mixed with 1 mL of 200 lmol/L DNPH
in 1 mol/L HCl. After 20 minutes at room temperature,
the amount of reacted carbonyls was determined by mea-
suring absorbance at 380 nm [21]. Measurements from
glyoxylate sample at the start of the incubation were used
as reference values to calculate fraction of reactive car-
bonyl groups. Readings from control sample containing
only 15 mmol/L pyridoxamine were the same as those
from buffer.
Statistical analysis
Effects were tested by post-hoc Student-Newman-
Keuls comparisons. Relationships between the urine
chemistries and crystal scores were assessed with Pear-
son correlations. All statistical analyses were performed
using SPSS version 9.0 (SPSS, Chicago, IL, USA). P ≤
0.05 was taken to signify statistical significance.
RESULTS
Effect of pyridoxamine treatment on urinary
oxalate excretion
In our experiments, the dose of pyridoxamine for an-
imal treatment (180 mg/day/kg body weight) was cho-
sen based on the results of long-term animal studies in a
diabetic rat model, where similar or higher pyridoxam-
ine doses were safe and had therapeutic affects [22, 23].
Animals in all experimental groups showed no adverse
effects. No significant differences in weight gain were
detected for the duration of the experiment (data not
shown). Animals with experimental hyperoxaluria (ethy-
lene glycol group) exhibited about a fourfold increase
in urinary oxalate excretion, consistent with previously
published data [17]. Pyridoxamine treatment of these ani-
mals (ethylene glycol + pyridoxamine group) caused dra-
matic and sustained decrease in urinary oxalate excretion
(Fig. 2A). In a separate experiment, pyridoxamine was
discontinued after a significant reduction in oxalate ex-
cretion was achieved (Fig. 2B). This caused an increase in
urinary oxalate excretion to the levels found in untreated
hyperoxaluric animals, confirming that the observed
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Fig. 2. Effect of pyridoxamine (PM) treatment on urinary oxalate ex-
cretion in animals with experimental hyperoxalura. Sprague-Dawley
male rats (49 to 52 days old) were randomized on day 1 to receive ei-
ther ethylene glycol (0.75% vol/vol in drinking water (450 mg/day/kg
body weight) (ethylene glycol group) or no treatment (control group).
After day 14, animals within each group [control (•) or ethylene gly-
col ()] were pair-matched according to their oxalate level. One mem-
ber of each pair was then randomly assigned to receive pyridoxamine
(3 mg/mL or 180 mg/day/kg body weight) either in drinking water [pyri-
doxamine ()] or in 0.75% ethylene glycol [ethylene glycol + pyridox-
amine ()]. Urine samples were collected under toluene (to inhibit
bacteria growth) in 50 mL tubes with hydrochloric acid to minimize
spontaneous breakdown of urinary ascorbic acid to oxalate. Urinary
oxalate was measured as described in the Methods section. Each sym-
bol represents mean value ± SE (N = 5); at the time points indicated
by asterisks, differences between ethylene glycol group and ethylene
glycol + pyridoxamine group were statistically significant (P < 0.05).
(A) Pyridoxamine was given continuously starting from day 14. (B) In
a separate experiment, pyridoxamine treatment started on day 14 and
was discontinued on day 28. In this experiment, the elevated levels of
oxalate excretion in control group on day 3 are most likely related to
animal adaptation. Note that the oxalate levels went down and leveled
off before the beginning of pyridoxamine treatment.
effect is dependent on the pyridoxamine treatment
(Fig. 2B). In the ethylene glycol group, increase in ox-
alate excretion was accompanied by the elevated ex-
cretion of oxalate precursor glycolate (Fig. 3C and D).
Elevated levels of urinary glycolate are often present in
primary hyperoxaluria type 1 patients [24]. The pyridox-
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Fig. 3. Effect of pyridoxamine (PM) treatment on urinary calcium, cre-
atinine, glycolate, and oxalate. The timing and dosing of treatment were
as in Figure 2B, except ethylene glycol (EG) was 0.8% vol/vol in drink-
ing water and pyridoxamine treatment continued until the end of the
experiment. Urinary calcium, creatinine, glycolate and oxalate were de-
termined in 24-hour urine samples collected on day 28 of pyridoxamine
treatment as described in the Methods section. Each bar represents
mean value ± SE; asterisks indicate a significant difference between
ethylene glycol group and ethylene glycol + pyridoxamine group (P <
0.05). Control group, N = 3; ethylene glycol group, N = 9; ethylene
glycol + pyridoxamine group, N = 8.
amine treatment lowered excretion of glycolate along
with excretion of oxalate suggesting that pyridoxamine
interferes with the flow of intermediates through glyoxy-
late pathway (Fig. 3C and D). The pyridoxamine treat-
ment did not significantly affect either urinary creatinine
or urinary calcium concentrations (Fig. 3A and B).
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Fig. 4. Formation of calcium oxalate crystals in rat kidney. Animals from the experiment described in Figure 3 were euthanazed on day 28 of
pyridoxamine (PM) treatment and kidneys removed. The crystals were analyzed in the hematoxylin-eosin–stained paraffin kidney sections under
polarized light as described in the Methods section. The representative slides for each treatment group are shown; for the ethylene glycol (EG)
group, the papillary and the medullary areas of the kidney are presented on separate slides. The statistical analysis of all experimental data is
presented in the Table 1.
With the proposed experimental design, we were
concerned about possible interference between pyri-
doxamine and ethylene glycol because they were both
administered in drinking water. If significant spontaneous
oxidation of ethylene glycol occurs in solution, the re-
sulting carbonyl moieties may react with the pyridoxam-
ine amino group. To address this question, we measured
the amount of reactive pyridoxamine amino groups in
incubations with ethylene glycol using trinitrobenzene-
sulfonic acid (TNBS) assay [25]. No change in amino
groups was detected after 24 hours at room temperature
(data not shown).
Effect of pyridoxamine treatment on
kidney crystal formation
The microscopic analysis of kidney tissue sections un-
der the polarized light showed a dramatic increase in
crystal formation in the ethylene glycol group compared
to control group (Fig. 4). There was also an apparent
decrease in crystal formation in hyperoxaluric animals
upon pyridoxamine treatment (Fig. 4) (ethylene glycol +
pyridoxamine group). In the ethylene glycol group, the
most crystals were formed in papilla followed by medulla
(Table 1). The least crystals were formed in cortex, where
the difference was not statistically significant compared
to the control group.
There was a direct relationship between urinary ox-
alate and kidney crystal deposition, most prominently in
papilla (Fig. 5), with the correlation coefficient (r=0.77)
approaching the overall reliability of scoring (r=0.84).
The data from the three treatment groups formed three
clusters with the exception of one outlier data point
in the ethylene glycol + pyridoxamine group (Fig. 5,
closed squares), indicating that the pyridoxamine treat-
ment was effective in eight out of nine animals (Fig. 5,
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Table 1. Scores of kidney crystal deposition in different treatment
groups
Kidney anatomic area
Treatment group Papilla Medulla Cortex
Control (N = 3) 0.00 0.021 ± 0.036 0.042 ± 0.036
Ethylene glycol 1.292 ± 0.855a 0.569 ± 0.665a 0.354 ± 0.521
(N = 9)
Ethylene glycol + 0.391 ± 0.461b 0.125 ± 0.257b 0.063 ± 0.058
pyridoxamine
(N = 8)
Animals from the experiment described in Figure 3 were euthanazed on
day 28 of pyridoxamine treatment and the kidneys removed. The crystals were
analyzed in hematoxylin-eosin–stained paraffin kidney sections under polarized
light as described in the Methods section. Data represent the mean ± SD.
aDifference between control group and ethylene glycol group is significant
(P < 0.02).
bDifference between ethylene glycol group and ethylene glycol + pyridoxam-
ine group is significant (P < 0.02).
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Fig. 5. Correlation between urinary oxalate excretion and papillary
crystal deposition. Symbols represent values from individual animals in
the same experiment as in Figures 3 and 4. EG is ethylene glycol; EG
+ PM is ethylene glycol + pyridoxamine.
open squares). The outlier was apparently due to lack
of responsiveness to pyridoxamine in this single animal,
since its treatment or behavior (including water consump-
tion or urine output) were similar to the rest of the group.
Because the urinary oxalate reading of the outlier data
point was outside the margin of 2 SD of the mean, this
data point was removed from statistical analysis. The sta-
tistical analysis of the data demonstrated that the pyri-
doxamine treatment of hyperoxaluric animals (ethylene
glycol + pyridoxamine group) resulted in a significant
decrease in crystal formation compared to the ethylene
glycol group in both papilla and medulla of the kidney
(Table 1).
Trapping of glyoxylate by pyridoxamine
We have previously demonstrated that pyridoxam-
ine can react with low-molecular-weight carbonyl com-
pounds, including oxalate precursor glycolaldehyde [14].
These results suggested that pyridoxamine may lower
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Fig. 6. Trapping of glyoxylate by pyridoxamine. Glyoxylate
(10 mmol/L) was incubated either alone () or with 15 mmol/L
pyridoxamine (•). The carbonyl groups of glyoxylate were determined
using 2,4-dinitrophenylhydrazine (DNPH) as described in the Methods
section.
urinary oxalate excretion by trapping carbonyl interme-
diates of oxalate biosynthesis. In the present study, we
demonstrated that another oxalate precursor, glyoxylate,
can potentially be a target for pyridoxamine. In the in
vitro incubations, pyridoxamine trapped glyoxylate via
reaction involving the carbonyl group (Fig. 6).
DISCUSSION
A number of pharmacological approaches have been
tested in an attempt to develop a therapy for hyperox-
aluria that targets oxalate biosynthesis. One approach is
to inhibit the enzymes involved in glyoxylate pathway
(Fig. 1). Several inhibitors of either aldehyde dehydroge-
nase or glycolate oxidase have been tested in animals
and in humans with mixed results [26, 27]. Newer in-
hibitors of aldehyde dehydrogenase such as fomepizole
were recently proposed for treatment of ethylene glycol
poisoning [28] and may potentially be used for kidney
stone therapy. However, this intravenous drug is not ap-
propriate for a long-term use, and may produce alcohol
intolerance. Another drawback of this approach may be
the accumulation of glycolaldehyde, a potential cytotoxic
agent.
An alternative approach to reduction of urinary ox-
alate concentration is based on the use of pyridoxine, a
precursor of pyridoxal-5′-phosphate (PLP), to enhance
the activity of AGT (Fig. 1). The mechanism of this ef-
fect is not entirely clear, but may relate to the ability
of PLP to modulate the expression of AGT or due to
enhancement of residual AGT activity by PLP [29, 30].
Because the primary mode of pyridoxine action is the
modulation of AGT expression and/or activity, individual
Chetyrkin et al: Pyridoxamine inhibition of kidney stone formation 59
differences in enzyme status render a majority of primary
hyperoxaluria type 1 patients non-responsive to pyridox-
ine treatment. As a result, this treatment provides sig-
nificant benefits only to a minority of patients, those with
vitamin B6–dependent type 1 primary hyperoxaluria [31].
The reports of the effects of pyridoxine in individuals with
idiopathic kidney stone disease are controversial, show-
ing no convincing reduction in oxalate excretion or su-
persaturation. For example, the intake of pyridoxine in
doses of 40 mg/day was associated with reduced risk of
kidney stone formation in women but not in men in lim-
ited studies [32, 33]. On the other hand, prescription of
200 mg of pyridoxine daily did not reduce urinary oxalate
levels in stone formers [34].
Another approach that targets AGT is suggested by
the work of Danpure et al [1], which demonstrated that
mutations causing peroxisome-to-mitochondrion mistar-
geting of the enzyme in primary hyperoxaluria type 1
patients result in destabilization of the AGT dimer. Thus,
the use of molecular chaperones or other compounds that
would either stabilize the dimeric AGT or increase the
rate of dimer formation may be a potential avenue for de-
velopment of new treatments for primary hyperoxaluria
type 1 [1].
A different approach to reducing hyperoxaluria is to
trap oxalate precursors in liver and reduce the amount
available for conversion to oxalate (Fig. 1). One of the
proposed treatments relies on reactivity of the carbonyl
group of glyoxylate with the free sulfhydryl group of cys-
teine. It has been suggested that this approach has a sig-
nificant potential because of the proximity of glyoxylate
to the terminal step in oxalate synthesis. The cysteine
precursor, (L)-2-oxothiazolidine-4-carboxylate (OTZ) is
used as the therapeutic agent because of its lower tox-
icity. OTZ has been shown to decrease urinary oxalate
concentration in the rat model of hyperoxaluria [35].
Treatment with OTZ also resulted in decreased urinary
oxalate levels in normal humans [36]. In a limited study
(one placebo-controlled primary hyperoxaluria type 1 pa-
tient), OTZ lowered plasma oxalate levels but the differ-
ence was not significant [37]. A potential drawback of
this method is that, at elevated levels, free cysteine can
interfere with a variety of reduction-oxidation reactions
in the cell and is potentially cytotoxic.
In this paper, we establish pyridoxamine as a new
prospective therapeutic agent for treatment of primary
hyperoxaluria and calcium oxalate stone formation. Our
results demonstrate that pyridoxamine treatment can
lower urinary oxalate excretion and kidney crystal for-
mation in rats with experimental hyperoxaluria. The
pyridoxamine may act through trapping of carbonyl
intermediates of oxalate biosynthesis glycolaldehyde and
glyoxylate. The adducts between pyridoxamine and these
oxalate precursors can form in vitro [14] (Fig. 6). Since
pyridoxamine is a B6 vitamin, it could also enhance AGT
activity, thus decreasing the amount of glyoxylate avail-
able for conversion to oxalate (Fig. 1). However, the en-
hancement of AGT activity is likely to be a minor part
of the pyridoxamine mechanism because pyridoxamine
is about sixfold less efficient as a PLP precursor com-
pared to pyridoxine [38]. Thus, we hypothesize that in
the course of treatment, circulating pyridoxamine is taken
up by the liver where it traps carbonyl intermediates of
oxalate biosynthesis. This trapping by pyridoxamine or
by its phosphorylated form, pyridoxamine-5′-phosphate
(PMP), occurs via adduct formation through the nucle-
ophilic amino group [14]. Pyridoxine, a vitamin B6 pre-
cursor used in the treatment of vitamin B6–dependent
primary hyperoxaluria, cannot trap these intermediates
because it does not possess an amino group. The conver-
sion of pyridoxine to pyridoxamine is a minor pathway of
vitamin B6 metabolism [38]; when rat liver was perfused
with radioactively labeled pyridoxine, less than 1% of it
was converted to pyridoxamine [39]. Conversion of pyri-
doxine to PMP is also limited because of the tight regula-
tion of pyridoxine(pyridoxamine)-5′-phosphate oxidase
by product inhibition [40, 41].
The efficacy of pyridoxamine treatment demonstrated
by our work, coupled with a favorable pyridoxamine
safety profile shown in Phase II clinical trials in diabetes
mellitus and controls [abstract; Williams ME, et al, J Am
Soc Nephrol 14:7A, 2003], suggests that pyridoxamine
has potential as a therapeutic agent for primary hyper-
oxaluria or recurrent calcium oxalate stone formation. If
proven effective, pyridoxamine could play an important
role in kidney stone preventive therapies.
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